AI companies like Anthropic create a dangerous innovation divide by offering tiered model access. A select few get powerful, unrestricted versions ("Mythos"), while the public gets a censored version ("Fable"), effectively creating a technological underclass and stifling widespread entrepreneurial opportunity.

When a billion-dollar drug trial fails, society learns nothing from the operational process. The detailed documentation of regulatory interactions, manufacturing, and trial design—the "lab notes" of clinical development—is locked away as a trade secret and effectively destroyed, preventing collective industry learning.

The most significant challenge with AI is the mass exodus of top researchers from universities and government to a few tech giants. This "hemorrhaging of talent" concentrates knowledge in the private sector, making it nearly impossible for the public to effectively govern or regulate the technology.

The current trend toward closed, proprietary AI systems is a misguided and ultimately ineffective strategy. Ideas and talent circulate regardless of corporate walls. True, defensible innovation is fostered by openness and the rapid exchange of research, not by secrecy.

By restricting its most powerful model, Mythos, to a consortium of large companies, Anthropic is creating a two-tier economy. Smaller companies are left without access to the same advanced offensive and defensive AI capabilities, ending the previously democratic access to cutting-edge models and creating a significant competitive disadvantage.

The closed nature of leading US AI models has created an information vacuum. Sridhar Ramaswamy notes that academia is now diverging from US industry and instead building upon published work from Chinese companies, which poses a long-term risk to the American innovation ecosystem.

Contrary to the idea of AI for all, the most powerful models will likely be restricted to a few high-paying clients to prevent distillation and maximize revenue. This creates a future where competitive advantage is defined by exclusive AI access, potentially allowing large incumbents to crush smaller competitors.

The "golden era" of big tech AI labs publishing open research is over. As firms realize the immense value of their proprietary models and talent, they are becoming as secretive as trading firms. The culture is shifting toward protecting IP, with top AI researchers even discussing non-competes, once a hallmark of finance.

Slowing public releases of AI models for government review may not slow overall progress. This creates a scenario where labs advance internally for months, giving government agencies exclusive access while delaying public commercialization and the next cycle of investment.